Together, the study provides insights into the immunosuppressive mechanism driven by BHLHE22 in prostate cancer and proposes a potential combination therapy approach involving immune checkpoint therapy and targeting CSF2 and PRMT5 for patients with BHLHE22-positive Prostate cancer with bone metastasis (89). The gene discussed is PRMT5; the disease is prostate carcinoma.